Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab

Blood

Volumn 100, Issue 5, 2002, Pages 1715-1720

  Buggins, Andrea G S ^a   Mufti, Ghulam J ^a   Salisbury, Jonathan ^a   Codd, Jane ^a   Westwood, Nigel ^a   Arno, Matthew ^a   Fishlock, Keith ^a   Pagliuca, Antonio ^a   Devereux, Stephen ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD52 ANTIGEN; CD56 ANTIGEN; GLYCOPROTEIN P 15095; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; PHOSPHATIDYLINOSITOL;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CELL LINEAGE; CELL MATURATION; DENDRITIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MIXED LYMPHOCYTE REACTION; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0036721489     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v100.5.1715.h81702001715_1715_1720     Document Type: Article

References (24)

1. The CAMPATH-1 antigen (CDw52)
2. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis
3. Humanized monoclonal antibody therapy for rheumatoid arthritis
4. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
5. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody
6. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement
7. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)
8. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may Increase the risk of leukaemic relapse
9. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection
10. In vivo CAMPATH prevents graft-versus-host disease following nonmyeioablative stem cell transplantation
11. Preliminary experience of allogenelc stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: An effective regimen with low procedure-related toxicity
12. Prevention of graft versus host disease by inactivation of host antigen-presenting cells
13. Identification of hematopoietic progenitors of macrophages and dendritic langerhans cells (DL-CFU) in human bone marrow and peripheral blood
14. Role of antibody to S100 protein in diagnostic pathology
15. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature
16. Human peripheral blood contains two distinct lineages of dendritic cells
17. A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells
18. Differential expression of CD52 by distinct myeloid dendritic cell subsets: Implications for the separation of graft-vs-host disease from graft-vs-tumor effect at the level of antigen presentation
19. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis
20. Campath-1M - Prephylactic use after kidney transplantation. A randomized controlled clinical trial
21. Subcutaneous CAMPATH in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia
22. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
23. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia
24. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question